The nephrology drug approval feed returned four routine supplemental items today and the enforcement feed was empty, so there is no new regulatory action of clinical consequence. The feeds do not reach KDIGO, ASN, ERA or ISN publications issued as web documents, nor CDSCO notices.
The guidance that matters is a KDIGO commentary on where newly approved therapies fit in IgA nephropathy. The context explains why it exists. KDIGO updated its glomerular disease guideline in 2021 and revised the IgA nephropathy section again in 2025 — and then three further treatments received accelerated approval from the FDA after that revision went to press. Because two of them work by mechanisms different from previously approved drugs, the work group issued a commentary rather than waiting for a full guideline cycle.
That sequence is itself the story. IgA nephropathy has moved from a disease with supportive care and little else to one where the guideline cannot keep pace with approvals, and the commentary is an explicit acknowledgement that the evidence for sequencing these agents does not yet exist.
For practice the implication is caution rather than enthusiasm. Accelerated approval means a surrogate endpoint — proteinuria reduction — rather than demonstrated preservation of kidney function, and the commentary is placing these drugs pending additional evidence. Optimised supportive care, meaning maximally tolerated renin-angiotensin blockade, blood pressure control and an SGLT2 inhibitor, remains the foundation on which any of these agents is added, not a step to be skipped because a targeted therapy exists.
- Read the KDIGO commentary before adding a newly approved agent in IgA nephropathy — the guideline itself predates these approvals
- Optimise supportive care first: maximally tolerated renin-angiotensin blockade, blood pressure control and an SGLT2 inhibitor
- Remember accelerated approval rests on proteinuria reduction, not on demonstrated preservation of kidney function
- Expect sequencing guidance to change; the work group explicitly issued this pending further evidence
- Note the coverage gap: KDIGO, ASN, ERA, ISN and CDSCO documents do not reach this feed
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free